http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102149483-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7068 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7068 |
| filingDate | 2013-10-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-102149483-B1 |
| titleOfInvention | Use of masitinib for treatment of cancer in patient subpopulations identified using predictor factors |
| abstract | The present invention relates to a method of treating cancer patients, wherein the patients are treated with a tyrosine kinase inhibitor, a mast cell inhibitor, or a c-Kit inhibitor, especially macitinib, and optionally at least one antitumor Agents can be used in combination. A tyrosine kinase inhibitor, a mast cell inhibitor or a c-Kit inhibitor, and any at least one anti-tumor agent are administered as a dosage regimen comprising a therapeutically effective amount. The present invention also relates to a method of predicting a treatment response to said treatment in a given patient, and thus to the identification of applicable patient subpopulations based on these predictor factors (sometimes referred to as biomarkers). Also do. One method is based on clinical markers of pain intensity. The second method is based on the evaluation of biomarkers predicting gene expression through RNA expression in a collection of peripheral blood cells prior to treatment with the compounds of the present invention (i.e. tyrosine kinase inhibitors, mast cell inhibitors or c-Kit inhibitors, especially Citinib). Advantageously, the present invention relates to a method of treating patients suffering from pancreatic cancer, wherein the patients are treated with a tyrosine kinase inhibitor, a mast cell inhibitor or a c-Kit inhibitor, in particular macitinib, optionally at least One antitumor agent, in particular gemcitabine, can be used in combination. |
| priorityDate | 2012-10-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 605.